Alaunos Therapeutics Inc.
TCRT | NASDAQ
$1.26
+$0.06 (+5.00%)
At close: Sep 21, 2026, 4:00 PM ET
$1.26
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:38 PM ET
Market Data
Market Cap $2.93M
Enterprise Value $2.95M
Beta -0.97
Average Volume 14.13K
Shares Outstanding (Diluted) 2.43M
Shares Change YoY 45.06%
Institutional Ownership 6.46%
Exchange NASDAQ
ISIN US98973P3091
Price Performance
Price Change 1M -28.8%
Price Change 3M -41.4%
Price Change 6M -58.1%
Price Change YTD -61.6%
Price Change 1Y -49.2%
Price Change 3Y -93.4%
Price Change 5Y -99.6%
1M CAGR (ann.) -39.7%
1Y CAGR (ann.) -50.0%
5Y CAGR (ann.) -66.5%
All-Time CAGR -27.8%
Valuation
PE Ratio -0.65
Forward PE N/A
PEG Ratio -0.03
Forward PEG 0.04
PS Ratio 1,025.70
Forward PS 0.00
PB Ratio 4.72
P/FCF Ratio -1.09
P/Adj. FCF Ratio -0.99
P/OCF Ratio -1.12
EV/Sales 984.37
EV/EBIT -0.97
EV/EBITDA -0.74
EV/FCF -1.05
Earnings Yield -154.8%
FCF Yield -91.8%
Adj. FCF Yield -100.7%
Financial Health
Net Cash $124K
Total Debt $0
Cash & Short-Term Investments $124K
Total Assets $1.52M
Current Ratio 0.77
Quick Ratio 0.77
Debt / Equity Ratio 0.00
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage 0.00
Altman Z-Score -860.46
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin -28133.3%
Operating Profit Margin -135266.7%
EBITDA Margin -132866.7%
Net Profit Margin -133666.7%
FCF Margin -94166.6%
Adj. FCF Margin -103333.3%
SBC / Revenue 9166.7%
SBC Impact (per share) -9.7%
Returns
Return on Assets -264.5%
Return on Equity -232.6%
Return on Invested Capital -622.4%
Return on Capital Employed -622.4%
Return on Tangible Assets -264.5%
Historical Growth (CAGR)
Revenue CAGR 3Y -89.9%
Revenue CAGR 5Y -55.6%
Revenue CAGR 10Y -54.2%
EPS CAGR 3Y 91.7%
EPS CAGR 5Y 59.8%
EPS CAGR 10Y 19.8%
FCF CAGR 3Y 94.7%
FCF CAGR 5Y 55.3%
FCF CAGR 10Y 17.2%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 0
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date Nov 16, 2026
EPS Estimate (next Q) -$15.75
EPS Growth Est (next Q) 2763.6%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Cash Flow
Operating Cash Flow $-2.73M
Free Cash Flow $-2.82M
Adj. Free Cash Flow $-3.1M
FCF Per Share -$1.16
OCF Per Share -$1.12
OCF/S Ratio -90900.0%
Income Statement
Revenue $3K
Gross Profit $-835K
Operating Income $-4.06M
EBITDA $-4M
Net Income $-4.01M
EPS (Diluted) -$1.95
Revenue / Employee $3K
Profit / Employee $-4.01M
Employees 1
Add to Watchlist
Select watchlists to add or remove TCRT